Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2020 Aug 27;31(6):649-658.
doi: 10.1515/revneuro-2020-0001.

The potential anti-depressant properties of dexmedetomidine infusion: a review of mechanistic, preclinical, and clinical evidence

Mohammed Al-Alawi  1   2 , Elisa Brietzke  1 , Adriana Carvalhal  1 , Claudio N Soares  1
Affiliations
Review

The potential anti-depressant properties of dexmedetomidine infusion: a review of mechanistic, preclinical, and clinical evidence

Mohammed Al-Alawi et al. Rev Neurosci. .

Abstract

Major depressive disorder (MDD) is a highly prevalent and disabling condition for which the currently available treatments are not fully effective. Existing unmet needs include rapid onset of action and optimal management of concurrent agitation. Dexmedetomidine (DEX) is a selective and potent α2-adrenergic receptor (α2-AR) agonist, with unique pharmacokinetic and pharmacodynamic properties. In this review, we discuss pre-clinical and clinical studies which focused on DEX in the context of its putative antidepressant effects for the management of MDD. Preliminary data support DEX as an antidepressant with fast onset of action, which would be especially helpful for patients experiencing treatment resistant depression, and agitation. We further explore the mechanistic and clinical implications of considering DEX as a putative antidepressant agent, and the next steps to explore the efficacy of low dose DEX infusion among patients with treatment resistant depression.

Keywords: antidepressant; dexmedetomidine; treatment resistant-depression.

PubMed Disclaimer

References

    1. Alam, A., Suen, K.C., Hana, Z., Sanders, R.D., Maze, M., and Ma, D. (2017). Neuroprotection and neurotoxicity in the developing brain: an update on the effects of dexmedetomidine and xenon. Neurotoxicol. Teratol. 60: 102–116, https://doi.org/10.1016/j.ntt.2017.01.001.
    1. Alexander, S.P., Davenport, A.P., Kelly, E., Marrion, N., Peters, J.A., Benson, H.E., Faccenda, E., Pawson, A.J., Sharman, J.L., Southan, C., et al. (2015). The concise guide to Pharmacology 2015/16: g protein-coupled receptors. Br. J. Pharmacol. 172: 5744–5869, https://doi.org/10.1111/bph.13348.
    1. Baarslag, M.A., Allegaert, K., Knibbe, C.A.J., van Dijk, M., and Tibboel, D. (2017). Pharmacological sedation management in the paediatric intensive care unit. J. Pharm. Pharmacol. 69: 498–513, https://doi.org/10.1111/jphp.12630.
    1. Biccard, B.M., Goga, S., and Buers, J.D. (2008). Dexmedetomidine and cardiac protection for non-cardiac surgery: a meta-analysis of randomised controlled trials. Anaesthesia 63: 4–14, https://doi.org/10.1111/j.1365-2044.2007.05306.x.
    1. Bougarel, L., Guitton, J., Zimmer, L., Vaugeois, J.M., and El Yacoubi, M. (2011). Behaviour of a genetic mouse model of depression in the learned helplessness paradigm. Psychopharmacology (Berl) 215: 595–605, https://doi.org/10.1038/npp.2008.23.

MeSH terms

LinkOut - more resources